Reported about 10 hours ago
MDxHealth SA has successfully completed the acquisition of Bio-Techne Corporation’s ExoDx business for $15 million, as part of its strategy to enhance its precision diagnostics portfolio. The acquisition includes the ExoDx Prostate test and features a payment structure over several years, aiming to strengthen the company’s offerings in prostate cancer and UTI detection, a significant market valued at $4.9 billion.
Source: YAHOO